The CAR-T First-Mover Advantage: Reality or Myth?

Posted by Sharon Karlsberg on Mar 12, 2019 8:00:00 AM

Robert Rovner co-wrote this blog post with Sharon Karlsberg. This article originally appeared in the January 2019 issue of OBR Green.

The “first-mover advantage” is something we’ve come to expect in the commercial world. The first to innovate and come to market usually reaps the greatest rewards, right? Facebook, Uber and Google improved on technology brought to market by actual first-movers MySpace, Sidecar and AltaVista, but then transcended them by addressing their weaknesses.


>
Read More

Biosimilars in Action at ASH 2018

Posted by Prateek Yadav on Dec 21, 2018 9:12:11 AM

Amy Leigh Niedzwecki co-wrote this blog post with Prateek Yadav.

At the 2018 Annual Society of Hematology (ASH) Annual Meeting, held Dec. 1-4 in San Diego, biosimilars were often top of mind. Within the hematology and oncology space, Rituxan (rituximab), Neupogen (filgrastim) and Neulasta (pegfilgrastim) are currently the most sought-after biologics for developing biosimilars, and the studies presented at the conference were limited to these three blockbuster biologics.

Here are our top three takeaways from this year’s event:


>
Read More

Going Beyond the Buzz of CAR-T Therapy

Posted by Robert Rovner on Dec 21, 2017 10:21:09 AM

There’s no doubt that chimeric antigen receptor T-cell (CAR-T) therapies have been generating increased interest over the past four years at the American Society of Hematology’s (ASH) Annual Meeting. In 2014, 34 abstracts on CAR-T therapies were presented at ASH, a number that more than tripled to 110 abstracts by 2016. This year, more than 140 CAR-T abstracts were presented to a packed Georgia World Congress Center in Atlanta. While some questions about this novel approach to cancer treatment remain unanswered, one thing is for certain: CAR-T therapies are here to stay. 


>
Read More

Upending the Treatment Paradigm in AML

Posted by Nathan Noll on Dec 19, 2017 9:40:13 AM

Sony introduced the Walkman in 1979. At the time, it was revolutionary, but when compared with the technology available today, it is woefully outmatched.


>
Read More

Multiple Myeloma at ASH 2017: Observations and Analysis

Posted by Josh Hattem on Dec 14, 2017 9:11:58 AM

There were 935 abstracts related to multiple myeloma accepted into the 2017 American Society of Hematology (ASH) Annual Meeting, or roughly one piece of new research for every 127 multiple myeloma patients in the U.S., according to the National Cancer Institute.


>
Read More